S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.58 (-1.61%)
AAPL   165.24 (-1.08%)
MSFT   400.69 (-0.89%)
META   482.49 (-3.85%)
GOOGL   153.89 (-1.36%)
AMZN   174.97 (-2.37%)
TSLA   148.16 (-1.18%)
NVDA   792.58 (-6.39%)
AMD   148.15 (-4.47%)
NIO   3.83 (-4.25%)
BABA   69.03 (+0.22%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   107.33 (-4.11%)
GE   148.98 (-2.59%)
CGC   8.02 (+2.43%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.09 (-0.02%)
XOM   119.91 (+1.17%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NovoCure Limited stock logo
NVCR
NovoCure
$12.02
-0.2%
$14.84
$10.87
$83.60
$1.29B0.421.36 million shs413,786 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$200.95
-0.4%
$235.92
$180.93
$348.67
$7.78B0.51340,772 shs151,745 shs
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$328.07
+0.2%
$282.20
$157.00
$331.58
$12.27B0.92957,510 shs899,957 shs
Teleflex Incorporated stock logo
TFX
Teleflex
$206.12
-0.6%
$226.40
$177.63
$276.43
$9.71B1.11255,213 shs135,812 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NovoCure Limited stock logo
NVCR
NovoCure
0.00%-14.66%-11.00%-13.81%-81.12%
Penumbra, Inc. stock logo
PEN
Penumbra
-3.23%-9.21%-15.48%-19.31%-26.35%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
+0.01%-0.20%+17.28%+50.80%+24.89%
Teleflex Incorporated stock logo
TFX
Teleflex
-0.41%-4.67%-4.90%-15.98%-22.76%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
NovoCure Limited stock logo
NVCR
NovoCure
4.5238 of 5 stars
4.34.00.04.52.42.50.0
Penumbra, Inc. stock logo
PEN
Penumbra
4.9342 of 5 stars
4.43.00.03.82.42.53.1
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
4.3402 of 5 stars
2.02.00.04.63.42.53.1
Teleflex Incorporated stock logo
TFX
Teleflex
4.8126 of 5 stars
3.33.01.73.92.82.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
NovoCure Limited stock logo
NVCR
NovoCure
2.56
Moderate Buy$31.13158.94% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.78
Moderate Buy$304.4551.51% Upside
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
2.09
Hold$309.11-5.78% Downside
Teleflex Incorporated stock logo
TFX
Teleflex
2.60
Moderate Buy$267.5029.78% Upside

Current Analyst Ratings

Latest NVCR, PEN, TFX, and SWAV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $28.00
4/8/2024
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$361.00 ➝ $335.00
4/8/2024
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
4/8/2024
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$270.00 ➝ $335.00
4/8/2024
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$285.00 ➝ $335.00
4/5/2024
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/5/2024
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$263.00 ➝ $335.00
4/5/2024
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/5/2024
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Peer Perform
4/3/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$49.00 ➝ $42.00
4/3/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$290.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
NovoCure Limited stock logo
NVCR
NovoCure
$509.34M2.54N/AN/A$3.39 per share3.55
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06B7.35$2.72 per share73.80$30.55 per share6.58
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$730.23M16.80$4.32 per share75.93$18.12 per share18.11
Teleflex Incorporated stock logo
TFX
Teleflex
$2.97B3.26$18.64 per share11.06$94.49 per share2.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
NovoCure Limited stock logo
NVCR
NovoCure
-$207.04M-$1.95N/AN/AN/A-40.65%-51.63%-17.90%5/2/2024 (Confirmed)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$2.3186.9950.492.068.59%7.49%5.60%5/7/2024 (Confirmed)
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$147.28M$3.8784.7752.662.4320.17%23.97%12.78%5/13/2024 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
$356.33M$7.5327.3713.561.9911.98%14.98%8.87%5/2/2024 (Confirmed)

Latest NVCR, PEN, TFX, and SWAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$0.42N/A-$0.42N/AN/AN/A  
5/2/2024N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$0.42N/A+$0.42N/AN/AN/A  
5/2/2024N/A
Teleflex Incorporated stock logo
TFX
Teleflex
$3.07N/A-$3.07N/AN/AN/A  
2/22/2024Q4 2023
NovoCure Limited stock logo
NVCR
NovoCure
-$0.53-$0.45+$0.08-$0.45$133.80 million$133.80 million      
2/22/2024Q4 2023
Penumbra, Inc. stock logo
PEN
Penumbra
$0.71$0.76+$0.05$0.14$286.62 million$284.68 million      
2/22/2024Q4 23
Teleflex Incorporated stock logo
TFX
Teleflex
$3.26$3.38+$0.12$6.10$769.01 million$773.90 million      
2/15/2024Q4 2023
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
$0.92$1.16+$0.24$1.16$199.43 million$202.98 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
N/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$1.360.66%N/A18.06%N/A

Latest NVCR, PEN, TFX, and SWAV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/22/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Quarterly$0.340.57%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
NovoCure Limited stock logo
NVCR
NovoCure
1.57
5.78
5.56
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.06
3.49
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
1.09
11.76
10.73
Teleflex Incorporated stock logo
TFX
Teleflex
0.39
2.32
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
95.35%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
NovoCure Limited stock logo
NVCR
NovoCure
5.67%
Penumbra, Inc. stock logo
PEN
Penumbra
5.30%
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
3.40%
Teleflex Incorporated stock logo
TFX
Teleflex
1.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,453107.61 million101.51 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.70 million36.65 millionOptionable
Shockwave Medical, Inc. stock logo
SWAV
Shockwave Medical
1,46837.40 million36.13 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,50047.10 million46.43 millionOptionable

NVCR, PEN, TFX, and SWAV Headlines

SourceHeadline
Allspring Global Investments Holdings LLC Buys 16,110 Shares of Teleflex Incorporated (NYSE:TFX)Allspring Global Investments Holdings LLC Buys 16,110 Shares of Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 19 at 4:50 AM
Teleflex Incorporated (NYSE:TFX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesTeleflex Incorporated (NYSE:TFX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
americanbankingnews.com - April 19 at 2:34 AM
Which Is a Better Investment, Rxsight Inc or Teleflex Inc Stock?Which Is a Better Investment, Rxsight Inc or Teleflex Inc Stock?
aaii.com - April 18 at 1:09 PM
Teleflex Announces First Quarter 2024 Earnings Conference Call InformationTeleflex Announces First Quarter 2024 Earnings Conference Call Information
globenewswire.com - April 18 at 6:30 AM
Cerity Partners LLC Buys Shares of 13,175 Teleflex Incorporated (NYSE:TFX)Cerity Partners LLC Buys Shares of 13,175 Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 18 at 5:40 AM
Raymond James Financial Services Advisors Inc. Trims Holdings in Teleflex Incorporated (NYSE:TFX)Raymond James Financial Services Advisors Inc. Trims Holdings in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 15 at 4:27 AM
DekaBank Deutsche Girozentrale Has $1.74 Million Position in Teleflex Incorporated (NYSE:TFX)DekaBank Deutsche Girozentrale Has $1.74 Million Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 14 at 5:19 AM
Guru Fundamental Report for TFX - Benjamin GrahamGuru Fundamental Report for TFX - Benjamin Graham
nasdaq.com - April 13 at 9:49 AM
Sequoia Financial Advisors LLC Makes New $1.72 Million Investment in Teleflex Incorporated (NYSE:TFX)Sequoia Financial Advisors LLC Makes New $1.72 Million Investment in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 13 at 6:40 AM
Teleflex Incorporated (NYSE:TFX) Shares Sold by Lawson Kroeker Investment Management Inc. NETeleflex Incorporated (NYSE:TFX) Shares Sold by Lawson Kroeker Investment Management Inc. NE
marketbeat.com - April 11 at 3:56 PM
Villere ST Denis J & Co. LLC Reduces Stock Position in Teleflex Incorporated (NYSE:TFX)Villere ST Denis J & Co. LLC Reduces Stock Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 8 at 12:23 PM
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATCTeleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
zacks.com - April 8 at 9:21 AM
Teleflex Unveils Advanced Tissue Control for UroLift 2 System, Revolutionizing BPH TreatmentTeleflex Unveils Advanced Tissue Control for UroLift 2 System, Revolutionizing BPH Treatment
msn.com - April 5 at 10:39 AM
Boston Trust Walden Corp Has $56.82 Million Holdings in Teleflex Incorporated (NYSE:TFX)Boston Trust Walden Corp Has $56.82 Million Holdings in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 4 at 11:30 PM
Teleflex catheterization kit recall linked to 10 injuries, 1 deathTeleflex catheterization kit recall linked to 10 injuries, 1 death
medtechdive.com - April 4 at 2:34 PM
Research Analysts Issue Forecasts for Teleflex Incorporateds FY2025 Earnings (NYSE:TFX)Research Analysts Issue Forecasts for Teleflex Incorporated's FY2025 Earnings (NYSE:TFX)
marketbeat.com - April 3 at 6:31 AM
Teleflex launches UroLift 2 with advanced tissue controlTeleflex launches UroLift 2 with advanced tissue control
massdevice.com - April 2 at 5:35 PM
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate TypesTeleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
finance.yahoo.com - April 2 at 8:41 AM
Teleflex Sets Ambitious Climate Targets, Validated by Science Based Targets InitiativeTeleflex Sets Ambitious Climate Targets, Validated by Science Based Targets Initiative
msn.com - April 1 at 12:54 AM
AMI Asset Management Corp Has $18.86 Million Stock Position in Teleflex Incorporated (NYSE:TFX)AMI Asset Management Corp Has $18.86 Million Stock Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - March 30 at 11:21 PM
LGT Capital Partners LTD. Purchases 190,950 Shares of Teleflex Incorporated (NYSE:TFX)LGT Capital Partners LTD. Purchases 190,950 Shares of Teleflex Incorporated (NYSE:TFX)
marketbeat.com - March 29 at 9:43 AM
Teleflex Incorporated (NYSE:TFX) Short Interest Down 42.0% in MarchTeleflex Incorporated (NYSE:TFX) Short Interest Down 42.0% in March
marketbeat.com - March 28 at 10:30 AM
Teleflex’s Climate Targets Validated by the Science Based Targets InitiativeTeleflex’s Climate Targets Validated by the Science Based Targets Initiative
finance.yahoo.com - March 28 at 8:09 AM
Teleflexs Climate Targets Validated by the Science Based Targets InitiativeTeleflex's Climate Targets Validated by the Science Based Targets Initiative
globenewswire.com - March 28 at 6:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

NovoCure logo

NovoCure

NASDAQ:NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Penumbra logo

Penumbra

NYSE:PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Shockwave Medical logo

Shockwave Medical

NASDAQ:SWAV
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Teleflex logo

Teleflex

NYSE:TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.